Journal Article Cites Cleanascite™ To Deplete Extracellular Vesicles

News Release

Journal Article Cites Cleanascite™ To Deplete Extracellular Vesicles


MONMOUTH JUNCTION, NJ, June 14, 2018 -- Biotech Support Group reports on a recent journal article describing the simplicity and efficiency of their lipid binding sample preparation technology for depleting the influence of extracellular vesicles – also known as EVs or exosomes, on cell-cell communication. The citation is:


Nguyen, Doan C., et al. "Extracellular vesicles from bone marrow-derived mesenchymal stromal cells support ex vivo survival of human antibody secreting cells." Journal of extracellular vesicles 7.1 (2018): 1463778.


Bone marrow-derived mesenchymal stromal cells (MSC) have been shown to support human antibody secreting cells (ASC) survival ex vivo. Extracellular vesicles from bone marrow-derived mesenchymal stromal have novel mechanisms of cell-cell communication over short and long distances, but whether the crosstalk between these cell interactions can occur via extracellular vesicles is not known. Thus, the study investigated the role of extracellular vesicles (EVs) in antibody secreting cell survival and IgG secretion. The article states “To understand whether disrupting the lipid plasma membrane that upsets the integrity of the EVs would compromise the survival activity of either the non-irradiated or irradiated secretomes, …We then cultured ASC with conventional media (vehicle), secretome from irradiated MSC, or secretome from irradiated MSC that had been pretreated with the lipid-disrupting agent Cleanascite [28], which is known not to alter protein functionality [29]. Cleanascite-treatment of the secretome dramatically reduced ASC functional survival, … Similar reductions were also noted with the secretome of non-irradiated MSC when treated with Cleanascite … These results demonstrate that lipid-membrane bodies, such as EVs, could mediate important ASC survival factors within the MSC secretome.”


This reference shows that Cleanascite™ can simply and efficiently bind the lipid membrane complex necessary for studying extracellular vesicle communication between cells. This demonstrates the advantage of using an aqueous suspension product with no solvents, to deplete lipid associated factors that may influence cell response investigations. The exosome depletion is quite impressive” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.   


For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm



About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com 


Contact:

Matthew Kuruc 732-274-2866

mkuruc@biotechsupportgroup.com